Targeting EBV‐encoded products: Implications for drug development in EBV‐associated diseases

Advances for pharmacological activities of Polygonum cuspidatum - A review

(2023) Jia Ke et al.   PHARMACEUTICAL BIOLOGY

Contribution of Epstein–Barr Virus Lytic Proteins to Cancer Hallmarks and Implications from Other Oncoviruses

(2023) Mike Dorothea et al.   Cancers

Immunotherapy for nasopharyngeal carcinoma: Current status and prospects (Review)

(2023) Huageng Huang et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

A bivalent Epstein-Barr virus vaccine induces neutralizing antibodies that block infection and confer immunity in humanized mice

(2022) Chih-Jen Wei et al.   Science Translational Medicine

How Does Epstein–Barr Virus Interact With Other Microbiomes in EBV-Driven Cancers?

(2022) Yuxi Wen et al.   Frontiers in Cellular and Infection Microbiology

JAK/STAT Signaling: Molecular Targets, Therapeutic Opportunities, and Limitations of Targeted Inhibitions in Solid Malignancies

(2022) Bilal Rah et al.   Frontiers in Pharmacology

The eIF4A Inhibitor Silvestrol Blocks the Growth of Human Glioblastoma Cells by Inhibiting AKT/mTOR and ERK1/2 Signaling Pathway

(2022) Wei Zhang et al.   Journal of Oncology

PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?

(2022) Yan Peng et al.   Frontiers in Oncology

PD-1/PD-L1 Pathway: A Therapeutic Target in CD30+ Large Cell Lymphomas

(2022) Wei Xie et al.   Biomedicines

EBV-associated diseases: Current therapeutics and emerging technologies

(2022) Srishti Chakravorty et al.   Frontiers in Immunology

In Vitro Safety, Off-Target and Bioavailability Profile of the Antiviral Compound Silvestrol

(2022) Susanne Schiffmann et al.   Pharmaceuticals

Targeting G-quadruplexes to achieve antiviral activity

(2022) Emanuela Ruggiero et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Epstein–Barr Virus (EBV) Epithelial Associated Malignancies: Exploring Pathologies and Current Treatments

(2022) Oren Shechter et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Targeting the PD-1/ PD-L1 interaction in nasopharyngeal carcinoma

(2021) David Johnson et al.   ORAL ONCOLOGY

Immunization with Epstein–Barr Virus Core Fusion Machinery Envelope Proteins Elicit High Titers of Neutralizing Activities and Protect Humanized Mice from Lethal Dose EBV Challenge

(2021) Xinle Cui et al.   Vaccines

Thymoquinone, as a Novel Therapeutic Candidate of Cancers

(2021) Belal Almajali et al.   Pharmaceuticals

Resveratrol for cancer therapy: Challenges and future perspectives

(2021) Boxu Ren et al.   CANCER LETTERS

Unlocking G-Quadruplexes as Antiviral Targets

(2021) Ardavan Abiri et al.   PHARMACOLOGICAL REVIEWS

Molecular Basis of Epstein–Barr Virus Latency Establishment and Lytic Reactivation

(2021) Takayuki Murata et al.   Viruses-Basel

Statins affect cancer cell plasticity with distinct consequences for tumor progression and metastasis

(2021) Madeleine Dorsch et al.   Cell Reports

Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases

(2021) Xinle Cui et al.   Frontiers in Immunology

Immune System Disorders, Cancer and Viral Infections: A New Treatment Opportunity for the Immune Checkpoint Inhibitors

(2021) Alejandro Olivares-Hernández et al.   Life-Basel

The different activities of RNA G-quadruplex structures are controlled by flanking sequences

(2021) Alice J-L Zheng et al.   Life Science Alliance

Novel EBV LMP-2-affibody and affitoxin in molecular imaging and targeted therapy of nasopharyngeal carcinoma

(2020) Shanli Zhu et al.   PLoS Pathogens

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

(2020) Michael Wang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting Epstein-Barr Virus in Nasopharyngeal Carcinoma

(2020) Pok Man Hau et al.   Frontiers in Oncology

Statin use and safety concerns: an overview of the past, present, and the future

(2020) Rubina Mulchandani et al.   Expert Opinion On Drug Safety

Structure-based design of small-molecule inhibitors of EBNA1 DNA binding blocks Epstein-Barr virus latent infection and tumor growth

(2019) Troy E. Messick et al.   Science Translational Medicine

Novel Therapeutics for Epstein–Barr Virus

(2019) Graciela Andrei et al.   MOLECULES

Epstein-Barr virus strain variation and cancer

(2019) Teru Kanda et al.   CANCER SCIENCE

Novel cationic Bis(acylhydrazones) as modulators of Epstein–Barr virus immune evasion acting through disruption of interaction between nucleolin and G-quadruplexes of EBNA1 mRNA

(2019) Oksana Reznichenko et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Prophylactic and therapeutic strategies for Epstein–Barr virus-associated diseases: emerging strategies for clinical development

(2019) Vijayendra Dasari et al.   Expert Review of Vaccines

Epstein-Barr virus (EBV) activates NKL homeobox gene HLX in DLBCL

(2019) Stefan Nagel et al.   PLoS One

Thymoquinone (2-Isoprpyl-5-methyl-1, 4-benzoquinone) as a chemopreventive / anticancer agent: Chemistry and Biological effects

(2019) Anas Ahmad et al.   SAUDI PHARMACEUTICAL JOURNAL

Treatment with Statins in Elderly Patients

(2019) Ruxandra-Nicoleta Horodinschi et al.   Medicina-Lithuania

CD137 Co-Stimulation Improves The Antitumor Effect Of LMP1-Specific Chimeric Antigen Receptor T Cells In Vitro And In Vivo

(2019) Xiaojun Tang et al.   OncoTargets and Therapy

Curcumin Inhibits Proliferation of Epstein–Barr Virus-Associated Human Nasopharyngeal Carcinoma Cells by Inhibiting EBV Nuclear Antigen 1 Expression

(2019) Limei Liu et al.   Biomed Research International

A novel Epstein–Barr virus-latent membrane protein-1-specific T-cell receptor for TCR gene therapy

(2018) Hyun-Il Cho et al.   BRITISH JOURNAL OF CANCER

Counteracting survival functions of EBNA3C in Epstein-Barr virus (EBV)-driven lymphoproliferative diseases by combination of SAHA and bortezomib

(2018) Kwai Fung Hui et al.   Oncotarget

The Immunomodulatory Capacity of an Epstein-Barr Virus Abortive Lytic Cycle: Potential Contribution to Viral Tumorigenesis

(2018) Abigail Morales-Sánchez et al.   Cancers

Epstein–Barr Virus-Associated Malignancies: Roles of Viral Oncoproteins in Carcinogenesis

(2018) Ahmed El-Sharkawy et al.   Frontiers in Oncology

In Cellulo Protein-mRNA Interaction Assay to Determine the Action of G-Quadruplex-Binding Molecules

(2018) Rodrigo Prado Martins et al.   MOLECULES

Immunogenic particles with a broad antigenic spectrum stimulate cytolytic T cells and offer increased protection against EBV infection ex vivo and in mice

(2018) Dwain G. van Zyl et al.   PLoS Pathogens

Production of virus-like particles for vaccines

(2017) J. Fuenmayor et al.   New Biotechnology

Affibody Molecules in Biotechnological and Medical Applications

(2017) Stefan Ståhl et al.   TRENDS IN BIOTECHNOLOGY

Nucleolin directly mediates Epstein-Barr virus immune evasion through binding to G-quadruplexes of EBNA1 mRNA

(2017) María José Lista et al.   Nature Communications

EBV induces persistent NF-κB activation and contributes to survival of EBV-positive neoplastic T- or NK-cells

(2017) Honami Takada et al.   PLoS One

Curcumin, the golden nutraceutical: multitargeting for multiple chronic diseases

(2016) Ajaikumar B Kunnumakkara et al.   BRITISH JOURNAL OF PHARMACOLOGY

Epstein-Barr virus lytic reactivation regulation and its pathogenic role in carcinogenesis

(2016) Hongde Li et al.   International Journal of Biological Sciences

PD-1–PD-L1 immune-checkpoint blockade in B-cell lymphomas

(2016) Aaron Goodman et al.   Nature Reviews Clinical Oncology

Rabbits immunized with Epstein-Barr virus gH/gL or gB recombinant proteins elicit higher serum virus neutralizing activity than gp350

(2016) Xinle Cui et al.   VACCINE

ERK2 phosphorylation of EBNA1 serine 383 residue is important for EBNA1-dependent transactivation

(2016) Ka-Won Noh et al.   Oncotarget

Novel Epstein-Barr virus-like particles incorporating gH/gL-EBNA1 or gB-LMP2 induce high neutralizing antibody titers and EBV-specific T-cell responses in immunized mice

(2016) Elizabeth M. Perez et al.   Oncotarget

HDACs and HDAC Inhibitors in Cancer Development and Therapy

(2016) Yixuan Li et al.   Cold Spring Harbor Perspectives in Medicine

The translation inhibitor silvestrol exhibits direct anti-tumor activity while preserving innate and adaptive immunity against EBV-driven lymphoproliferative disease

(2015) John T. Patton et al.   Oncotarget

Statins and Cancer

(2014) Natalia Vallianou et al.   Anti-Cancer Agents in Medicinal Chemistry

Small molecule inhibition of Epstein–Barr virus nuclear antigen-1 DNA binding activity interferes with replication and persistence of the viral genome

(2014) Eun Kyung Lee et al.   ANTIVIRAL RESEARCH

Inhibition of Epstein-Barr Virus Lytic Cycle by an Ethyl Acetate Subfraction Separated from Polygonum cuspidatum Root and Its Major Component, Emodin

(2014) Ching-Yi Yiu et al.   MOLECULES

G-quadruplexes regulate Epstein-Barr virus–encoded nuclear antigen 1 mRNA translation

(2014) Pierre Murat et al.   Nature Chemical Biology

Cyclin-dependent kinases

(2014) Marcos Malumbres   GENOME BIOLOGY

Epstein-Barr virus and Burkitt lymphoma

(2014) Martin Rowe et al.   Chinese Journal of Cancer

Solution Structure of a G-quadruplex Bound to the Bisquinolinium Compound Phen-DC3

(2013) Wan Jun Chung et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

From Bortezomib to other Inhibitors of the Proteasome and Beyond

(2013) Daniela Buac et al.   CURRENT PHARMACEUTICAL DESIGN

Sustained Complete Responses in Patients With Lymphoma Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein-Barr Virus Latent Membrane Proteins

(2013) Catherine M. Bollard et al.   JOURNAL OF CLINICAL ONCOLOGY

Dasatinib therapy results in decreased B cell proliferation, splenomegaly, and tumor growth in a murine model of lymphoma expressing Myc and Epstein-Barr virus LMP2A

(2012) Jamie L. Dargart et al.   ANTIVIRAL RESEARCH

Small molecule and peptide-mediated inhibition of Epstein-Barr virus nuclear antigen 1 dimerization

(2012) Sun Young Kim et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Statin drug interactions and related adverse reactions

(2012) Stefano Bellosta et al.   Expert Opinion On Drug Safety

Thymoquinone Efficiently Inhibits the Survival of EBV-Infected B Cells and Alters EBV Gene Expression

(2012) Malek A. Zihlif et al.   INTEGRATIVE CANCER THERAPIES

Resveratrol Prevents EBV Transformation and Inhibits the Outgrowth of EBV-Immortalized Human B Cells

(2012) J. Luis Espinoza et al.   PLoS One

New mTOR Targets Grb Attention

(2011) S. S. Yea et al.   SCIENCE

Dasatinib, a Multikinase Inhibitor: Therapy, Safety, and Appropriate Management of Adverse Events

(2010) Sepideh Shayani   THERAPEUTIC DRUG MONITORING

STAT3 activation contributes directly to Epstein-Barr virus-mediated invasiveness of nasopharyngeal cancer cellsin vitro

(2009) Vivian Wai Yan Lui et al.   INTERNATIONAL JOURNAL OF CANCER

Antitumor Activity and Mechanism of Action of the Cyclopenta[b]benzofuran, Silvestrol

(2009) Regina Cencic et al.   PLoS One

p21 and p27: roles in carcinogenesis and drug resistance

(2008) Abde M. Abukhdeir et al.   EXPERT REVIEWS IN MOLECULAR MEDICINE

Stability and kinetics of G-quadruplex structures

(2008) A. N. Lane et al.   NUCLEIC ACIDS RESEARCH